Literature DB >> 8249052

Determination of the serum protein binding of oxycodone and morphine using ultrafiltration.

K P Leow1, A W Wright, T Cramond, M T Smith.   

Abstract

Protein binding of oxycodone and morphine in human serum was determined in vitro using ultrafiltration. Binding studies were also performed using both purified human serum albumin and human alpha 1-acid glycoprotein (AAG). Albumin was found to be the major binding protein for both oxycodone and morphine. The serum protein binding of both oxycodone and morphine was independent of drug concentration in the therapeutic range (5-100 ng/ml), but was dependent on protein concentration. In addition, bound fractions of oxycodone and morphine increased with increasing concentrations of both albumin and AAG. At physiological pH and temperature, the mean (+/- SD) serum protein binding of oxycodone was 45.1% (+/- 0.4%) and that of morphine was 35.3% (+/- 0.2%) A decrease in temperature from 37 to 23 degrees C significantly increased the serum protein binding of oxycodone and morphine by 8-9% (p < 0.0001) and 7-10% (p < 0.0001), respectively, indicating the importance of maintaining the temperature at 37 degrees C during protein binding experiments. A reduction in pH from 7.75-8.85 to 7.4 significantly reduced serum protein binding of both oxycodone and morphine by 4-5% (p < 0.0001) and 4-7% (p < 0.0001), respectively. Serum samples, to which known concentrations of oxycodone had been added and which were stored at -20 degrees C, showing a gradual but significant decline (p < 0.0001) in serum protein binding of oxycodone from approximately 45 to 39% during the 4-week storage period.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8249052     DOI: 10.1097/00007691-199310000-00014

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  14 in total

1.  Comparison of serum and lithium-heparinate plasma for the accurate measurements of endogenous and exogenous morphine concentrations.

Authors:  Alexis Laux-Biehlmann; Nadja Gräfe; Jinane Mouheiche; Denise Stuber; Ingeborg D Welters; François Delalande; Pierrick Poisbeau; Patrick Garnero; Marie-Hélène Metz-Boutigue; Francis Schneider; Yannick Goumon
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

2.  Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients.

Authors:  Takafumi Naito; Masaki Tashiro; Keisuke Yamamoto; Kazunori Ohnishi; Yoshiyuki Kagawa; Junichi Kawakami
Journal:  Eur J Clin Pharmacol       Date:  2012-03-23       Impact factor: 2.953

Review 3.  Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone.

Authors:  Mari Kinnunen; Panu Piirainen; Hannu Kokki; Pauliina Lammi; Merja Kokki
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

Review 4.  Oxycodone DETERx® ER Capsules: A Review in Severe, Chronic Pain.

Authors:  Yvette N Lamb; Karly P Garnock-Jones; Susan J Keam
Journal:  Drugs       Date:  2016-12       Impact factor: 9.546

Review 5.  Oxycodone/Ibuprofen combination tablet: a review of its use in the management of acute pain.

Authors:  Vicki Oldfield; Caroline M Perry
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  On-column entrapment of alpha1-acid glycoprotein for studies of drug-protein binding by high-performance affinity chromatography.

Authors:  Jeanethe Anguizola; Cong Bi; Michelle Koke; Abby Jackson; David S Hage
Journal:  Anal Bioanal Chem       Date:  2016-06-11       Impact factor: 4.142

7.  Human Fetal Liver Metabolism of Oxycodone Is Mediated by CYP3A7.

Authors:  Sara Shum; Nina Isoherranen
Journal:  AAPS J       Date:  2021-01-12       Impact factor: 4.009

8.  Electrochemical Detection of Morphine in Untreated Human Capillary Whole Blood.

Authors:  Elsi Verrinder; Niklas Wester; Elli Leppänen; Tuomas Lilius; Eija Kalso; Bjo Rn Mikladal; Ilkka Varjos; Jari Koskinen; Tomi Laurila
Journal:  ACS Omega       Date:  2021-04-21

9.  Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients.

Authors:  Trine Naalsund Andreassen; Pål Klepstad; Andrew Davies; Kristin Bjordal; Staffan Lundström; Stein Kaasa; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2010-12-08       Impact factor: 2.953

10.  Metabolism of oxycodone in human hepatocytes from different age groups and prediction of hepatic plasma clearance.

Authors:  Timo Korjamo; Ari Tolonen; Veli-Pekka Ranta; Miia Turpeinen; Hannu Kokki
Journal:  Front Pharmacol       Date:  2012-01-05       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.